Drug development targeting the ubiquitin-proteasome system (UPS) for the treatment of human cancers

Xiaonan Zhang, Stig Linder, Martina Bazzaro

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Cancer cells are characterized by a higher rate of protein turnover and greater demand for protein homeostasis compared to normal cells. In this scenario, the ubiquitin-proteasome system (UPS), which is responsible for the degradation of over 80% of cellular proteins within mammalian cells, becomes vital to cancer cells, making the UPS a critical target for the discovery of novel cancer therapeutics. This review systematically categorizes all current reported small molecule inhibitors of the various essential components of the UPS, including ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), ubiquitin ligases (E3s), the 20S proteasome catalytic core particle (20S CP) and the 19S proteasome regulatory particles (19S RP), as well as their mechanism/s of action and limitations. We also discuss the immunoproteasome which is considered as a prospective therapeutic target of the next generation of proteasome inhibitors in cancer therapies.

Original languageEnglish (US)
Article number902
JournalCancers
Volume12
Issue number4
DOIs
StatePublished - Apr 2020

Bibliographical note

Funding Information:
Funding: This work was supported by Department of Defense Ovarian Cancer Research Program Grant OC160377, the Minnesota Ovarian Cancer Alliance, the Randy Shaver Cancer Research Funds and the NIH grant 1R01GM130800-01A1 to Martina Bazzaro. The funders had no role in the decision to publish or preparation of the manuscript.

Keywords

  • Cancer
  • Chemoresistance
  • Targeted therapy
  • Ubiquitin

Fingerprint Dive into the research topics of 'Drug development targeting the ubiquitin-proteasome system (UPS) for the treatment of human cancers'. Together they form a unique fingerprint.

Cite this